Outcome of Board Meeting

Profit growth above 25%Related-party transactionsExceptional itemResults View source PDF Explain this filing

AMBALALSA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.4%Reaction day

₹32.81

prior close

₹33.60

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%+1.3% vs market

Pharmaceuticals peers, median of 164sector-0.1%+1.5% vs sector

On the reaction day the stock moved 1.3 pts more than Nifty Microcap 250 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

+2.7

15m

+2.1

30m

+0.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.4+0.1+1.3-0.1+1.5

Next day

-1.0+1.7-2.7+0.9-1.9

+0.2+2.4-2.2+0.9-0.7

+6.6+2.4+4.3+0.7+5.9

+8.5+1.7+6.8+0.8+7.7

+8.6+0.6+8.0+0.0+8.6

+8.8+1.9+6.9-0.1+8.9

15d

+0.7+4.9-4.2+1.2-0.4

-3.4+8.9-12.3+3.0-6.4

-4.4+7.5-11.9+4.7-9.1

+34.1+13.6+20.5+7.9+26.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The Board approved audited financial results for Q4 and FY ended March 2026. Consolidated revenue grew modestly by 3.1% to Rs 20,227 Lakhs from Rs 19,619 Lakhs. However, profit after tax surged dramatically to Rs 1,780 Lakhs from Rs 93 Lakhs - a 1,811% increase. EPS improved to Rs 2.32 from Rs 0.64. The jump in profitability was partly due to reversal of provisions no longer required and lower exceptional losses (Rs 82 Lakhs vs Rs 700 Lakhs previously). Pharmaceuticals segment contributed Rs 11,051 Lakhs and Electronics Rs 9,178 Lakhs to revenues. The statutory auditors issued unqualified opinions on both standalone and consolidated results. The Board also approved inter-corporate loans to three group companies (Asence Pharma, Synbiotics, Systronics India) and recommended re-appointment of key directors.

Likely market impact

The massive PAT growth is positive for shareholders but the modest revenue growth (3.1%) suggests profitability gains came mainly from one-time provisions rather than core business expansion. The unqualified audit opinion provides comfort on financial reporting quality.